Novartis ESMO Event Presentation

Vast majority of AEs were low-grade 177Lu-PSMA-617 (n = 227) 130 (57.3) Treatment-emergent adverse events in ≥ 10% patients in either arm AES, n (%) Dry mouth All grades ARPI change (n = 232) 5 (2.2) 177Lu-PSMA-617 (n = 227) 3 (1.3) Grades 3-5 ARPI change (n = 232) Asthenia Nausea 72 (31.7) 67 (28.9) 1 (0.4) 8 (3.4) 71 (31.3) 28 (12.1) 0 1 (0.4) Anaemia 55 (24.2) 39 (16.8) 14 (6.2) 14 (6.0) Fatigue 52 (22.9) 59 (25.4) 0 4 (1.7) Constipation 50 (22.0) 31 (13.4) 1 (0.4) 0 Decreased appetite 48 (21.1) 42 (18.1) 0 1 (0.4) Arthralgia 43 (18.9) 48 (20.7) 0 1 (0.4) COVID-19 37 (16.3) 26 (11.2) 1 (0.4) 1 (0.4) Diarrhoea 37 (16.3) 20 (8.6) 0 1 (0.4) Back pain 28 (12.3) 38 (16.4) 2 (0.9) 5 (2.2) 0 Vomiting 26 (11.5) 11 (4.7) 0 Oedema peripheral 19 (8.4) 26 (11.2) 0 Weight loss 15 (6.6) 28 (12.1) 2 (0.9) 0 5 (2.2) 25 NOVARTIS ESMO EVENT | OCTOBER 24, 2023 | INVESTOR PRESENTATION NOVARTIS | Reimagining Medicine

View entire presentation